{"eventGroups":[{"deathsNumAffected":6,"deathsNumAtRisk":100,"description":"Enrolled patients will be treated with ATG-010( 100 mg/QW, oral ) with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5cycles.","id":"EG000","otherNumAffected":100,"otherNumAtRisk":100,"seriousNumAffected":51,"seriousNumAtRisk":100,"title":"SVd (Selinexor+Bortezomib+Dexamethasone)"},{"deathsNumAffected":2,"deathsNumAtRisk":52,"description":"Enrolled patients will be treated with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5 cycles.","id":"EG001","otherNumAffected":51,"otherNumAtRisk":52,"seriousNumAffected":24,"seriousNumAtRisk":52,"title":"Vd(Bortezomib+Dexamethasone)"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.0","stats":[{"groupId":"EG000","numAffected":98,"numAtRisk":100},{"groupId":"EG001","numAffected":47,"numAtRisk":52}],"term":"Blood and lymphatic system disorders"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","stats":[{"groupId":"EG000","numAffected":90,"numAtRisk":100},{"groupId":"EG001","numAffected":40,"numAtRisk":52}],"term":"Metabolism and nutrition disorders"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","stats":[{"groupId":"EG000","numAffected":82,"numAtRisk":100},{"groupId":"EG001","numAffected":38,"numAtRisk":52}],"term":"Gastrointestinal system diseases"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":100},{"groupId":"EG001","numAffected":11,"numAtRisk":52}],"term":"Infectious pneumonia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.0","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":100},{"groupId":"EG001","numAffected":1,"numAtRisk":52}],"term":"Cataract"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.0","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":100},{"groupId":"EG001","numAffected":4,"numAtRisk":52}],"term":"Decreased platelet count"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":100},{"groupId":"EG001","numAffected":3,"numAtRisk":52}],"term":"Nervous system disease"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":100},{"groupId":"EG001","numAffected":2,"numAtRisk":52}],"term":"Respiratory system, thoracic and mediastinal diseases"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":100},{"groupId":"EG001","numAffected":4,"numAtRisk":52}],"term":"Gastrointestinal system diseases"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.0","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":100},{"groupId":"EG001","numAffected":2,"numAtRisk":52}],"term":"Heart diseases"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":100},{"groupId":"EG001","numAffected":1,"numAtRisk":52}],"term":"General disorders and administration site conditions"}],"timeFrame":"AEs: from first dose to 30 days post-last dose; SAEs: from consent to 30 days post-last dose. Total collection period: up to 2 years."}